These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9619864)

  • 1. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
    Sadzuka Y; Hirotsu S; Hirota S
    Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective prodrug liposome and conversion to active metabolite.
    Sadzuka Y
    Curr Drug Metab; 2000 Jul; 1(1):31-48. PubMed ID: 11467079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
    Sadzuka Y; Hirotsu S; Hirota S
    Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomalization of SN-38 as active metabolite of CPT-11.
    Sadzuka Y; Takabe H; Sonobe T
    J Control Release; 2005 Nov; 108(2-3):453-9. PubMed ID: 16182400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
    Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
    J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
    Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
    Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
    Iwase Y; Maitani Y
    Cancer Sci; 2012 Feb; 103(2):310-6. PubMed ID: 22017398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.
    Zhang Z; Yao J
    AAPS PharmSciTech; 2012 Sep; 13(3):802-10. PubMed ID: 22639238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
    Atsumi R; Okazaki O; Hakusui H
    Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
    Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
    Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
    Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Stable Irinotecan Liposome with Enhanced Antitumor Activity in a Range of Tumor Models.
    Su Z; Li L; Hao F; Zhao J; Li M; Zhao X; Zhao D
    Pharm Res; 2023 Dec; 40(12):3043-3058. PubMed ID: 37914843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
    Takeda S; Shimazoe T; Kuga H; Sato K; Kono A
    Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
    Prijovich ZM; Chen KC; Roffler SR
    Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model.
    Atsumi R; Okazaki O; Hakusui H
    Biol Pharm Bull; 1995 Jul; 18(7):1024-6. PubMed ID: 7581244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
    Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
    J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.